Truist Sticks With Buy on Praxis; Highlights Upside If Ulixa Prices Higher Than Base Case
Truist Securities reaffirmed a Buy rating on Praxis Precision Medicines (PRAX) and held a $500 price target, citing potential material upside from higher-than-expected pricing for ulixa in essential tremor. The firm’s base wholesale acquisition cost model is roughly $27,000 per year, but key opinion leaders signaled comfort with materially higher n…